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ABSTRACT: Microbioreactors play a critical role in process
development as they reduce reagent requirements and can facilitate
high-throughput screening of process parameters and culture
conditions. Here, we have demonstrated and explained in detail, for
the first time, the amenability of the automated ambr15 cell culture
microbioreactor system for the development of scalable adherent
human mesenchymal multipotent stromal/stem cell (hMSC)
microcarrier culture processes. This was achieved by first
improving suspension and mixing of the microcarriers and then
improving cell attachment thereby reducing the initial growth lag
phase. The latter was achieved by using only 50% of the final
working volume of medium for the first 24 h and using an
intermittent agitation strategy. These changes resulted in >150%
increase in viable cell density after 24 h compared to the original
process (no agitation for 24 h and 100%working volume). Using the
same methodology as in the ambr15, similar improvements were
obtained with larger scale spinner flask studies. Finally, this
improved bioprocess methodology based on a serum-based
medium was applied to a serum-free process in the ambr15,
resulting in>250% increase in yield compared to the serum-based
process. At both scales, the agitation used during culture was the
minimum required for microcarrier suspension, NJS. The use of the
ambr15, with its improved control compared to the spinner flask,
reduced the coefficient of variation on viable cell density in the
serum containing medium from 7.65% to 4.08%, and the switch to
serum free further reduced these to 1.06–0.54%, respectively. The
combination of both serum-free and automated processing
improved the reproducibility more than 10-fold compared to the
serum-based, manual spinner flask process. The findings of this
study demonstrate that the ambr15 microbioreactor is an effective
tool for bioprocess development of hMSC microcarrier cultures and
that a combination of serum-free medium, control, and automation
improves both process yield and consistency.
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Introduction
Human mesenchymal multipotent stromal/stem cells (hMSCs) are
considered a promising candidate for a cell-based therapies given
their propensity for growth in vitro, relative ease of isolation,
differentiation potential and their ability to secrete small
molecules which can aid the regeneration of damaged tissue
(Aggarwal and Pittenger, 2005). However the translation of this
promising research to clinical adoption will require, among other
factors, the successful development of scalable, sustainable,
robust, and consistent cell manufacturing processes (Rafiq and
Hewitt, 2015). There is a commercial and clinical need to expedite
cell therapy process development; small-scale, high-throughput
platforms provide a means to achieve this. Such technologies can
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improve efficiency, reduce costs, and accelerate time to market
while minimizing development resources (Bareither and Pollard,
2011; Pollard, 2014; Rafiq and Hewitt, 2015). Moreover, the
high-throughput nature of these technologies are amenable for
Quality by Design (QbD) tools such as factorial design of
experiments (DoE) which have become an integral part of
modern process development and manufacture.
It is well established that multifactorial statistical experimenta-
tion is necessary to identify and understand the complex
interaction between key variables and parameters to develop
optimal cell culture conditions which maintain product quality
attributes (Mitchell et al., 2014). Multiple small-scale, high-
throughput cell culture platforms have been developed to enable
this type of experimentation, including spinner and shake flasks
(ranging in minimum working volume from 50 to 250mL), bench-
top bioreactors (ranging in volume from 250mL to 5 L) and more
recently, microbioreactors. The latter term is a general one, covering
multiple types of devices (ranging in volume from 500mL to 30mL)
providing a range of scales and complexity including microtiter
plates to parallel arrays of fully monitored, controlled, and
automated miniature bioreactors (Hsu et al., 2012; Nienow et al.,
2013; Warr SRC, 2014).
For hMSC process development, the majority of the small-scale
work has been conducted in spinner flasks (Bardy et al., 2013; Dos
Santos et al., 2011a; Eibes et al., 2010; Ferrari et al., 2012; Goh et al.,
2013; Hewitt et al., 2011; Rafiq et al., 2013a; Schirmaier et al., 2014;
Schop et al., 2010). Although spinner flasks are easy to use and require
little training, these systems are restricted to surface aeration and are
limited with respect to experimental throughput. They also do not
provide an environmental control capability as found in traditional
benchtop bioreactors and are dependent on external control of
humidity, temperature, and oxygen concentration which is usually
achieved by being placed within an incubator (Hsu et al., 2012; Jossen
et al., 2014), which can have a significant laboratory footprint. In
addition, each vessel has to be manipulated individually and manually
with regard to medium exchange, which for many vessels takes
significant time often outside the controlled environment of the
incubator. To facilitate translation to the clinic, relevant, accurate,
small-scale, high-throughput experimental models need to be
developed which are representative of larger-scale, industrial systems
that will eventually be used for product manufacture.
To address the need for small-scale, high-throughput cell culture
technology, numerous systems have been developed including
microtiter plates (Legmann et al., 2009), microfluidic reactors
(Zanzotto et al., 2004) and small-scale automated bioreactors such
as the ambr15 cell culture system (Lewis et al., 2010). The ambr15
system is an automated, high-throughput bioreactor platformwhich
allows for 24 or 48 individually controlled, single-use stirred-tank
bioreactors (Fig. 1). Each bioreactor has automated online
monitoring and control for pH and dissolved oxygen (dO2). The
ambr15 platform has demonstrated significant success for biologics
production, where it was found to be equivalent with respect to cell
growth and protein titre with larger scale stirred systems (Hsu et al.,
2012; Lewis et al., 2010; Nienow et al., 2013). However, all
applications of the ambr15 system thus far have focused exclusively
on free suspension culture and yet many cell therapy candidates
including hMSCs are anchorage-dependent. As such, the expansion
of these cells in stirred-tank bioreactors, in most cases, requires the
use of microcarriers.
The aim of the work presented here is to show that the ambr15
microbioreactor system is a suitable scale-downmodel for larger scale
hMSC microcarrier culture. Since, microcarrier suspension is
considered critical for successful culture (Hewitt et al., 2011) and
the shape of the ambr15 (rectangular cuboid of aspect ratio >1
(Nienow et al., 2013), Fig. 1) is not optimal for suspension, it was
expected that modifications would be necessary; and this proved to be
so. These changes are therefore discussed first, leading to significant
improvements in performance. Once established, themodified ambr15
system and microbioreactors were then used for bioprocess
development, whereby studies were conducted to optimize hMSC
microcarrier culture conditions resulting in improved cell yields. These
findings were then validated in larger-scale vessels demonstrating
equivalent cell growth, viability, identity, and functionality.
Materials and Methods
hMSC Monolayer Expansion
Human MSCs from two donors were isolated from bone-marrow
aspirate obtained by Lonza (Walkersville, MD) after the donor
provided informed consent. The local Ethical Committee approved the
use of the samples for research. The hMSCs were isolated on the basis
of plastic adherence and cryopreserved at passage 1 at a density of
2 106 cells/mL in 10% dimethyl sulphoxide (DMSO)
(v/v) (Sigma–Aldrich, Dorset, UK) and 90% foetal bovine serum
(FBS; Hyclone, Lot# RUF35869). To expand hMSCs for microcarrier
experiments, hMSCs were cultured in monolayer as described in Rafiq
et al. (2013b). In brief, the hMSCs were seeded at 5,000 cells/cm2 and
cultured in DMEM (Lonza, Slough, UK) supplemented with 10% (v/v)
foetal bovine serum (FBS;HyClone) and 2mMUltraGlutamine (Lonza,
UK). Where cells were cultured under serum-free medium (SFM)
conditions, the Prime-XVTM SFM hMSC medium was used (Irvine
Scientific, Santa Ana, CA) in accordance with the manufacturer’s
instructions. As required, attachment surfaces were pre-coated with
recombinant fibronectin (Irvine Scientific) and the hMSCs underwent
one adaptation passage in medium containing SFM Prime-XVTM
medium. Viable cell number (via acridine orange uptake and DAPI
exclusion) and mean cell diameter were determined using a
NucleoCounter NC-3000 automated mammalian cell counter (Chemo-
metec, Lillerød, Denmark).
Spinner Flask Microcarrier Culture
A 100mL BellCo spinner flasks (Bellco Glass Inc., Vineland, NJ),
were used for all spinner flask experiments, with a 100mLworking
volume and a vessel diameter (T) of 60mM. For all microcarrier
cultures, Plastic P102-L microcarriers (Pall Life Sciences,
Portsmouth, UK) were employed (Rafiq et al., 2016). The same
inoculation concentrations and culture methods were employed as
described in Rafiq et al. (2016) except where improvements to the
process were made (discussed in the Results section). In brief, this
method employed 5 cm2 of microcarrier surface area per mL of
medium and an inoculation density of 6,000 cells/cm2. The spinner
flasks were agitated at the just suspended speed (NJS) which was
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30 rpm. When additional microcarriers were added as described in
later experiments NJS increased to 45 rpm.
ambr15 Microcarrier Culture
Prior to inoculation, ambr15 vessels with up-pumping impellers
were loaded onto the platform and stabilized with respect to pH
(7.2), temperature (37 C) and dO2 (100%). The original working
volume was set to 15mL and the original impeller speed for NJS was
300 rpm. This speed was subsequently increased to 400 rpm (as
described later) due to clump formation, preventing effective
suspension of the microcarriers as the culture progressed. The
hMSCs were cultured at the same seeding and microcarrier
concentration as the spinner flasks and cultured in complete growth
medium. The liquid handling program script was amended to
enable the system to sample the vessel at a user-set volume rather
than the standard factory setting which would sample from the
bottom of the vessel.
As with spinner flask culture, daily samples of the microcarrier
culture were taken throughout culture for cell viability and
supernatant analysis. Cells were counted while still attached to the
microcarriers using the NC-3000 NucleoCounter (Chemometec) as
directed by the manufacturer. Two approaches for sampling were
adopted during the course of this study. First, 250mL of the
microcarrier carrier was sampled daily as the vessels were agitated,
thus ensuring that a representative sample of the microcarrier
culture was obtained. The volume removed was replaced when a
medium exchange was performed. Additional studies were
performed where entire vessels were sacrificed at each time point.
This procedure was conducted to identify whether the daily removal
of a 250mL sample and replacement of medium during a medium
exchange had any effect on the culture. It was found that the daily
sampling method did not have any notable effect on the culture
(data not shown).
As described in Achieving equivalent hMSC growth in ambr15 and
spinner flasks section, a strategy employed to improve culture in the
ambr150 vessel involved aseptic siliconization of the vessel. This
processwas achieved by using a 0.2mMsyringe filter (Fisher Scientific,
Loughborough, UK) and manually adding the siliconizing agent,
Sigmacote (Sigma–Aldrich), to each vessel ensuring coverage of the
entire vessel surface area before aspirating. Vessels were left overnight
to dry in a fume hood and rinsed with distilled water after 24 h.
To achieve the higher cell densities described in Serum-free
expansion of hMSCs in ambr15 and spinner flasks section,
additional microcarriers were added to the vessels during the
exponential phase of growth when the cells were reaching densities
75,000 cells/cm2, a value which we have previously found to be
80% confluence in T-flasks for Prime-XV SFM cultures.
Microcarrier addition was based on the intention of achieving a
mean ratio of 50 cells/microcarrier and was calculated based on the
cell number in each vessel and the number of microcarriers in each
vessel at the point of addition.
Cell Characterization
Multi-parameter immunophenotypic analysis of the hMSCs was
determined by flow cytometry and the antibodies were selected on
the basis of the panel recommended by the International Society for
Cellular Therapy (ISCT) (Dominici et al., 2006). This was performed
using a Guava HT flow cytometer with excitation at 488 nM and is
described in detail in Chan et al. (2014). Tri-lineage differentiation
potential of the cells was determined by using the StemPro
Adipogenesis kit, StemPro Chondrogenesis kit and StemPro
Osteogenesis kit (Life Technologies, ThermoFisher Scientific
Company, Loughborough, UK) in accordance with the manufac-
turer’s instructions on post-harvest hMSC samples to induce
differentiation. Staining of the samples to determine differentiation
was performed as described in (Rafiq et al., 2013b). CFU-f efficiency
was determined by culturing the hMSCs in monolayer at a cell
density of 10 cells/cm2 and with a complete medium exchange every
4 days. After 15 days in culture, hMSCs were washed with PBS
(Lonza, Visp, Switzerland) and fixed with 4% formaldehyde (v/v)
Figure 1. Overview of the ambr15 microbioreactor. (A) The ambr15 automated platform including liquid handler and culture stations and (B) the ambr15 microbioreactor
spargeless vessel.
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(Sigma, UK) for 30min. A 1% crystal violet (Sigma–Aldrich) in
100% methanol (w/v) was used for colony staining. The samples
were incubated at room temperature for 30 min in the 1% crystal
violet solution. All stained colonies that comprised of more than 25
cells were recorded as CFUs.
Harvesting of hMSCs in Spinner Flasks
A detailed overview of the harvesting method and theoretical
principles are provided in (Nienow et al., 2014). Briefly, the
harvesting procedure involved a two-step process: (1) detachment
of the cells from the microcarriers using an increased agitation rate
of 150 rpm for 7min during enzymatic reagent exposure and (2)
separation of the cells and microcarriers prior to cell concentration
by filtration. After detachment and separation, >95% cells with
>95% viability were recovered (Nienow et al., 2016).
Harvesting of hMSCs in ambr15 Microbioreactor
The harvest procedure for the ambr15 was similar in principle to
that for the spinner flask harvest (Nienow et al., 2016). However, the
harvest was automated and performed by the device’s liquid
handler. Given the time taken by the liquid handler to aspirate spent
medium from each vessel (approximately 3min/vessel) and the fact
that 12 bioreactor vessels are operated on one culture station (and
therefore limited to one speed for all 12 bioreactor vessels), only two
vessels on each culture station were harvested at a time. This limit
was imposed in order to avoid prolonged exposure to trypsin which
can result in cell damage during extended waiting time. The
agitation rate for harvesting was originally 650 rpm for 7min
during enzymatic reagent exposure (6mL of either trypsin or
TryplE was used—each were equally effective (Nienow et al.,
2016)). However, as discussed later, the speed was subsequently
increased to 800 rpm to facilitate cell harvest from clumps formed
during culture. In that case, post filtration, more than 95% viable
cells were recovered (Nienow et al., 2016).
Analytical Techniques
Analysis of glucose and lactate concentrations in the spent medium
was performed using a Cedex Bio-HT (Roche,Mannheim, Germany).
The specific growth rate, cumulative population doublings, specific
metabolite consumption/production and coefficient of variation (CV)
were calculated for all samples (Rafiq et al., 2013b).
Statistical Analysis
For comparison between two data sets, statistical significance was
determined by using the Student’s two-tailed t-test. For comparison
of multiple data sets, significance was calculated by the one-way
ANOVA test with the Tukey post hoc correction test; significance
was determined at P< 0.05. GraphPad Prism 6 (La Jolla, CA) was
used for all statistical analysis.
Results
The objective of this work was two-fold: (1) to determine whether
the ambr15 microbioreactor, designed for free suspension culture,
could be adapted for small-scale, microcarrier culture; and (2), if so,
could the ambr15 platform then be used for serum-free bioprocess
development, which could be reproduced in a larger scale vessel.
Initial Adaptation of the ambr15 Microbioreactor
Geometry and Software for Microcarrier Culture
As hMSCs are anchorage-dependent and are traditionally grown on
microcarriers when cultured in stirred-tank bioreactors, it was first
necessary to adapt the system to enable microcarrier culture to be
undertaken successfully. This involved two key changes: (1) since
the original ambr15 has a sparger which extends close to the base of
the bioreactor, a spargeless vessel was used to prevent blockage and
backflow of microcarriers into the sparger (Fig. 1); and (2)
amendments to the liquid handler software script to enable
customizable liquid sampling points for medium exchange and
sampling without removing microcarriers (Fig. 1).
Initial hMSC Microcarrier Studies in the Modified ambr15
Microbioreactor
Human MSCs were cultured on microcarriers in both the ambr15
microbioreactor and spinner flasks with an equivalent surface area
of microcarriers to volume of medium ratio provided in both
systems. Growth in the spinner flask was significantly better
throughout the course of the culture, with a final viable cell density
of 1.78 105 0.26 cells/mL being achieved by 192 h in culture
compared with 0.73 105 0.09 cells/mL in the ambr15 (Fig. 2).
After completion of the culture, the vessels were visually inspected
and it was found that the vast majority of microcarriers were
clumped around the base of the impeller (Fig. 2B). This large
microcarrier clump was not extracted during the harvest
procedure. Therefore any cells growing within this clump were
unlikely to have been included in the count resulting in a low and
unrepresentative number.
Strategies to Avoid Clumping Around the Base of
Impeller
Strategies were considered as to how the extensive clumping around
the base of the impeller (Fig. 2B) could be avoided; and also, if any
clumps were to form, how the cells could be successfully harvested.
First, it was decided that a three-fold approach would be
implemented involving a change in agitation strategy. The agitator
configuration was changed from up-pumping to down-pumping, a
preferred mode for solid suspension without sparging (Nienow,
1997b) . Additionally, the agitation of the culture was stopped every
6 h for 1min over the first 24 h which prevented microcarrier
clumps forming around the base of the impeller. Finally, the
agitation rate during harvest was increased from 650 rpm to
800 rpm in order to increase the harvest of cells from any
microcarrier clumps that formed.
With this change in the process, there was no noticeable
clumping around the base of the impeller (Fig. 2D) and all the cells
on microcarriers in the vessel were extracted for harvest and
counted. This change significantly improved the cell density
achieved in the ambr15 with a final viable cell density of
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Figure 2. Growth of hMSCs from donor 1 cultured on microcarriers in serum-based medium in the ambr15 and spinner flasks with (A) the viable cell density in the initial run
where clumping around the ambr15 vessel impeller was a significant issue (B), the arrow illustrates microcarrier-cell clump formation around the base of the ambr15 impeller shaft.
(C) The viable cell density following changes to the agitator configuration (from up-pumping to down-pumping) and an increase in harvest agitation rate from 650 to 800 rpm which
encouraged cell detachment from larger microcarrier clumps. (D) Reduced clumping around the ambr15 impeller shaft but clumping in corners of the ambr15 vessel illustrated by the
arrow. (E) Viable cell density after further changes to avoid clumping including increasing the culture agitation rate from 300 to 400 rpm and aseptically siliconizing the vessel prior to
use. (F) Improved microcarrier suspension as indicated by the arrow with little/no clumping. Data show mean SD, n¼ 8. () Significance was determined at P< 0.05.
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1.20 105 cells/mL by 192 h being recorded. Although the
ambr15 demonstrated a similar trend in the growth compared to
the spinner flask, there was still a significantly lower final viable cell
density achieved in the former. After examination, it was noted that
clumping was still an issue. Instead of a large clump forming
around the base of the impeller as previously (Fig. 2B), clumps of
microcarriers (albeit smaller in size) were now forming in the
corners of the microbioreactor vessel (Fig. 2D).
Achieving Equivalent hMSC Growth in ambr15 and
Spinner Flasks
Microcarriers clumping in the corners of the ambr15 vessel
suggested that increased agitation intensity was required not only
during harvest but also during culture so it was increased from
300 rpm to 400 rpm. This speed was selected as it facilitated
suspension of microcarriers for the duration of the culture period.
In addition to further prevent microcarriers/cell clumps forming in
the vessel corners, the internal surfaces of the microbioreactor and
impeller were aseptically siliconized.
This combination of methods significantly improved the micro-
carrier suspension with them being well suspended throughout the
course of the culture with significantly less clumping (Fig. 2F).
As a result, the hMSC final viable cell density achieved in the
ambr15 culture was 1.51 0.06 cells/mL by 192 h (Fig. 2E)
which was similar to that of the spinner flask value of
1.59 105 0.06 cells/mL.
Bioprocess Development Using the ambr15
Microbioreactor System
The other key aim was to determine whether the system could be
used for improved bioprocess performance and if this improvement
could be validated in a larger-scale system. We identified that a
critical aspect of the culture which required optimization was the
inoculation and initial cell attachment period. The growth curves in
Figure 2E show a consistent, significant decrease in cell number
post-inoculation over the first 24 h for both ambr15 and spinner
flasks, which results in an extended lag phase in both systems.
Following investigation of a range of factors, it was found that two
parameters had the most significant impact in reducing the lag
period: the initial medium volume (volume of medium at the start
of the culture) and intermittent agitation over the first 24 h. The
adjustments in the two parameters formed what is subsequently
referred to as the “improved culture process protocol.” This
Figure 3. Comparison of hMSC donor 1 growth kinetics in ambr15 with the original and improved process cultured on microcarriers in serum-based medium, showing (A) the
viable cell density, (B) specific growth rate, (C) the cumulative population doublings and (D) the doubling time. Data show mean SD, n¼ 12.
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improved process differed from the original one in that the initial
working volume was reduced by 50% (7.5mL in the ambr15) for the
first 24 h before being increased to the maximumworking volume of
15mL. The improved process also involved an intermittent
agitation regime which consisted of 5 min agitation followed by
25min without agitation for the first 3 h of culture—after this time,
the culture was agitated continuously.
This “improved process” was directly compared with the
“original process” which retained medium volume at the
maximum working volume, 15 mL, and had a 1 h static period
post-inoculation which was followed by continuous agitation for
the duration of the culture (Fig. 3A). Instead of the viable cell
density dropping to 0.10 105 cells/mL after 24 h as was the
case with the original process (Fig. 3A), the viable cell density for
the improved process increased to 0.36 105 cells/mL. This
reduced the lag phase by 48 h and resulted in significantly higher
cell proliferation rate with a final viable cell density of
2.72 105 0.09 cells/mL by 192 h. Compared to the original
ambr15 process, the improved process resulted in >70% increase
in yield and this increase is reflected in the specific growth rate,
cumulative population doublings and doubling times measured
(Fig. 3B–D).
Validation of the ‘‘Improved Bioprocess’’ With the
Spinner Flask Culture System
Having developed an improved ambr15 process, similar conditions
were employed in the spinner flasks. This change meant using an
equivalent microcarrier concentration to medium volume ratio and
fill level to the ambr15 and an identical intermittent agitation
strategy. Figure 4 shows the culture of hMSCs in both the ambr15 and
the spinner flask using the “improved process.” The viable cell
densities throughout the culture are almost identical, following the
same trend of a reduced lag phase and a final viable cell density of
2.5 105 cells/mL; the viable cell densities at 192 h of both the
ambr15 and the spinner flasks were found not to be significantly
different (Fig. 4A). The similarity between the ambr15 and the
spinner flask using the improved process was also reflected in the
specific growth rates, cumulative population doublings, and doubling
times measured (Figs. 4B–D). In addition to the growth kinetics, the
metabolic activity of the cells in each culture systemwas similar; with
the specific glucose consumption10 pmol/cell/day and 10.5 pmol/
cell/day (Fig. 5A), specific lactate production19 pmol/cell/day and
20 pmol/cell/day (Fig. 5B), specific ammonia production 2.8 and
3.0 pmol/cell/day (Fig. 5C) and LDH29 and 30U/cell/day (Fig. 5D)
Figure 4. Validation of the improved ambr15 bioprocess with the larger-scale spinner flask for hMSC donor 1 cells showing (A) the viable cell density for donor 1, (B) specific
growth rate, (C) the cumulative population doublings and (D) the doubling time. Data show mean SD, n¼ 8.
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in the ambr15 and spinner flask, respectively. The similarity between
the two systems is further demonstrated by the functionality with
respect to colony forming unit efficiency (Fig. 6A) andmorphological
characteristics of the cells with respect to both mean cell diameter
(Fig. 6B) and cell growth on the microcarriers (Fig. 6C and D).
Cell identity and quality with respect to the immunophenotypic
expression, differentiation, and CFU-f potential was assessed and
cells on microcarriers taken from the ambr15 microbioreactor are
shown as brightfield (Fig. 7A) and fluorescent images (Fig. 7B); cells
in suspension after detachment are shown in Figure 7C. In addition,
hMSCs from both the ambr15 microbioreactor and the spinner
flasks that had been harvested at the end of each culture were also
assessed in accordance with the ISCT criteria (Dominici et al.,
2006), which demonstrated their trilineage differentiation potential
toward the osteogenic, chondrogenic, and adipogenic pathways
(Fig. 7D–F, respectively for the ambr15) and confirmation of their
immunphenotype (Fig. 7G). As in our earlier work, the cells from
the spinner flasks also met these criteria (Rafiq et al., 2013a) (data
not shown).
Although the growth kinetics and metabolic activity of the cells were
similar between the two systems, it was notable that there was a greater
level of variation in the spinner flask compared to the ambr15 system
across all of the measured parameters including cell density, mean cell
diameter and specificmetabolite production/consumption (Fig. 8). In all
cases, the coefficient of variation (CV) was lower using the ambr15
system compared to the spinner flasks, demonstrating that the ambr15
was amore consistent system for the growth of hMSCs onmicrocarriers
(Fig. 8), presumably because of the tighter control of pH and dO2.
Serum-Free Expansion of hMSCs in ambr15 and Spinner
Flasks
The process was then adapted to culture the hMSCs in serum-free
medium. Figure 9 illustrates a significant increase in yield obtained
with both the ambr15 and the spinner flask when using the serum-
free medium. The final viable cell density obtained with both the
ambr15 and spinner flask in the serum-free medium was
>8.1 105 cells/mL while the equivalent serum-based medium
studies yield was2.2 105 cells/mL, resulting in>250% increase
in yield (Fig. 9A). To accommodate, the increase in growth and
requirement for surface area, additional microcarrier surface area
was provided at 72 h and 120 h (as indicated by the arrows on
Fig. 9A). Additional surface area was aseptically transferred to the
culture to obtain a mean ratio of 50 cells/microcarrier. The amount
added was calculated from the cell number obtained from sampling
each vessel and the number of beads in the culture at the time of
addition. Though there were distinct differences in performance
with the different media, as with the study described in Validation of
the “Improved Bioprocess” With the Spinner Flask Culture System
section, the growth kinetics in the ambr15 and the spinner flask
were similar in both media; as represented by the viable cell
densities (Fig. 9A), the specific growth rates (Fig. 9B), the
cumulative population doublings (Fig. 9C) and the doubling time
(Fig. 9D). Likewise, when the study was repeated with an additional
BM-hMSC donor, the growth kinetics between the ambr15 and the
spinner flasks were similar (Supplementary Fig. S1). The overall cell
yield between the two donors was different; however such
differences between the two donors were also exhibited in
Figure 5. Specific metabolic activity for hMSC donor 1 cells with the ambr15 improved process and validated by the larger-scale spinner flask. The data show (A) the specific
glucose consumption, (B) specific lactate production, (C) the specific ammonia production and (D) the specific LDH production. Data show mean SD, n¼ 8.
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monolayer cultures (data not shown) and is attributed to donor-
to-donor variation.
Metabolite analysis of the serum-based and serum-free
medium expansion demonstrated a decrease in the glucose
concentration, particularly toward the latter stages of the cultures
which may have contributed to the decrease in cell concentration
in SFM conditions (Supplementary Fig. S2). There is a
concomitant increase in the concentration of both lactate and
ammonia. However, these do not reach levels which may inhibit
cell growth (Schop et al., 2010). The hMSCs cultured in SFM in
the ambr15 and spinner flask (data not shown) retained their
ability to differentiate toward the adipogenic, ostogenic, and
chondrogenic lineages and the expected immunphenotypic
expression (Supplementary Fig. S3).
When comparing the extent of variation between the two systems
(ambr15 and spinner flask) and themedia (serum-based and serum-
free), the ambr15 serum-free systemwas the most consistent process
with a CVof 0.54% while the equivalent serum-based process in the
ambr15 resulted in a CV of 4.08% (Fig. 10). The process which
demonstrated the greatest level of variability was the spinner flask
serum-based process which had a CV of 7.65% and the equivalent
serum-free spinner flask process had a CV of 1.06% (Fig. 10).
Discussion
With increasing reagent and medium costs and the need for high-
throughput capability, there is a demand for automated systems
which can operate at lower working volumes and offer greater levels
of parallelization. Clearly, the ambr15 cell culture system potentially
provides significant advantages over these other existing small-
scale bioreactor systems suitable for microcarrier culture because of
its higher-throughput capability (up to 48 microbioreactor vessels
can be run simultaneously), lower working volume requirements
(7–15mL) and automated liquid handling and culture operation.
Here, we have demonstrated, after some modifications, that the
ambr15 microbioreactor can be used successfully for hMSC culture
on microcarriers. Importantly, we also demonstrate that it can be
used to improve a microcarrier bioprocess. These results were
achieved by first improving the mixing and suspension of
the microcarriers in the vessel. In detail, this required recognizing
the challenges presented by the geometry of the ambr15 vessel
(Fig. 1B), in particular the propensity for microcarriers to settle and
form aggregates initially under the impeller and then subsequently
in the corners of the vessel. The strategy employed involved
siliconizing the vessel prior to use, changing the mode of agitation
Figure 6. Characterisation of hMSC donor 1 cells cultured with the ambr15 improved process and validated by the larger-scale spinner flask. The data show (A) colony forming
unit efficiency, (B) mean cell diameter, fluorescent staining illustrating viable (green), and non-viable (red) cells cultured in (C) the ambr15 and (D) spinner flask at different points
during culture.
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from up-pumping to down-pumping and increasing the agitation
speed (from 300 to 400 rpm) to ensure full suspension (Nienow,
1997b) during the expansion/culture phase. In addition, attach-
ment of cells to microcarriers was improved by lowering the initial
fill volume by 50% and providing an intermittent agitation regime.
These process changes have improved our baseline bioreactor
process and aligns with process development work conducted by
others where such strategies have been employed successfully to
improve cell attachment to microcarriers (Carmelo et al., 2015;
Frauenschuh et al., 2007; Yuan et al., 2012). In addition to ensuring
full suspension, these changes limited the extent of clumping
around the base and corners of the vessel and together with the
increase in agitator speed during harvesting (from 650–800 rpm),
ensured that as many cells as possible (>95%) were harvested.
Collignon et al. (2010) specified criteria for impeller selection
specifically for microcarrier culture which included: (1) maintain-
ing microcarriers in complete suspension; and (2) effective
homogeneity of culture medium. The down-pumping mode is
generally preferred for solid particle suspension including micro-
carriers (Ibrahim and Nienow, 2004) and enables them to be
suspended at a lower mean specific energy dissipation rate than
other impellers. In addition, they give similar mixing times to other
impellers at the same mean specific energy dissipation rates
(Nienow, 1997a). Here, this mode effectively ensured that the
microcarriers did not settle, clump together or form aggregates on
the base and in the corners of the microbioreactor vessel.
There is always concern regarding damage to both free suspension
cells and cells on microcarriers in stirred bioreactors and this aspect
of the current work has recently been discussed in detail (Nienow
et al., 2016) . The usually accepted criterion for damage on
microcarriers has been that the size of the Kolmogorov scale of
turbulence, lK should not be less than about 2/3rd the size of
microcarrier (Croughan et al., 1987); the microcarriers used in this
study (Plastic P102-L) have a diameter ranging from 112 to 212mM.
In this case, even with a down-pumping agitator at NJS (¼400 rpm),
themaximum local specific energydissipation rate, which defines the
minimumKolmogorov scale was estimated to be 0.142W/kg to give a
Kolmogorov scale (lK)JS of 52mM. Though smaller than the usually
accepted scale, the cells were still able to grow to confluence and
maintained their quality attributes with respect to differentiation
Figure 7. Functional characterization of hMSC donor 1 cells harvested from the improved ambr15 bioprocess. The data show (A) brightfield image of hMSCs growing on Plastic
P102-L microcarriers in the ambr15 microbioreactor vessel, (B) fluorescent staining of same cell-microcarrier image depicted in (A) with viable (green) and non-viable (red) cells. (C)
Single cells following detachment of hMSCs from the microcarriers using the ambr15 microbioreactor. Tri-lineage differentiation potential of hMSCs harvested from the ambr15
showing (D) Adipogenic, (E) osteogenic, and (F) chondrogenic differentiation of hMSCs. (G) Multiparameter flow cytometry showing dual gating of CD90, 105, 73, 34, and HLA-DR for
hMSCs post-harvest from the ambr15 microbioreactor.
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potential, CFU-f formation, and immunophenotype (Figs. 4, 7 and 9).
However, at the speed used for harvesting (800 rpm), the Kolmogorov
scale was reduced to 24mM (Nienow et al., 2014), which is greater
than the size of cells once they become detached from the
microcarriers during harvesting. In that case, they should not be
damaged and once again the cells maintained all their quality
attributes (Nienow et al., 2016).
In addition to ensuring adequate suspension of microcarriers,
the strategies implemented reduced the amount and extent of
clumping (Fig. 2B and C). A large clump such as those observed in
Figure 2 would have a severely reduced specific surface area
available for mass transfer of nutrients and metabolites to and from
the cells, thereby potentially limiting cell growth; and causing
possible nutrient/oxygen deprivation at the centre of the clump.
Previous work by Jorgensen and Tyers (2004) has demonstrated that
cells which experience such deprivation remain in the G1 phase of
the cell cycle for longer, thus resulting in a decrease in proliferation
potential. In addition, Ferrari et al. (2012) indicate the detrimental
effect of cell aggregation due to the reduced proliferative capacity
and highlight the potential for populations with unwanted
heterogeneity. They propose a method of avoiding cell aggregation
by the inclusion of additional fresh microcarriers during the culture
process. This concept is supported by our findings (Fig. 9) and that
of Dos Santos et al. (2011b), where the addition of fresh
microcarriers to the process was necessary to ensure the continued
proliferative capacity of the cells and to avoid clumping or
aggregation of cells. The addition of fresh microcarriers spreads the
cells more widely on the total increased microcarrier surface
available, promoting bead to bead transfer and increasing the area
of the cells in direct contact with the medium and available for mass
transfer. In addition, it reduces the likelihood of cells forming large
cell aggregates or large cell-microcarrier clumps if the additional
microcarriers are provided during the exponential phase of culture,
prior to cells reaching confluence.
The improved process that was developed using the ambr15
resulted in improved attachment and a reduction in the lag phase.
This improvement was achieved by two key aspects, namely
providing only 50% of the final working volume of medium for the
first 24 h in conjunction with an intermittent agitation strategy.
These strategies resulted in >150% increase in viable cell density
Figure 8. Comparison of extent of variation between the ambr15 and spinner flask for serum-based hMSC donor 1 microcarrier culture with data showing (A) viable cell density,
(B) mean cell diameter, (C) specific glucose consumption, (D) specific lactate production, (E) specific ammonia production, and (F) specific LDH production. Data show coefficient of
variation (CV), n¼ 12.
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after 24 h compared to the original process (no agitation for 24 h
and 100% working volume). We posit that these changes had a
significant impact on the initial attachment as it exposed the full
surface of the microcarrier to the cells and reduced the distance and
therefore time taken for the cells to reach the microcarrier surface.
The intermittent agitation also resulted in fewer microcarrier-cell
clumps and reduced cell aggregation. Studies have demonstrated that
intermittent agitation provides sufficient mass transfer, and prevents
the formation of aggregate formation, but more importantly, it also
exposes the full surface of themicrocarrier to the cells (Carmelo et al.,
2015; Frauenschuh et al., 2007; Hervy et al., 2014; Ting et al., 2014;
Wang and Ouyang, 1999; Yeatts et al., 2013; Yuan et al., 2012). In
addition to improving cell attachment and growth, intermittent
agitation can have a favorable effect on functionality. For example,
Ting et al. (2014) demonstrate that for human embryonic stem cell
(hESC) cultures, intermittent agitation is preferred to both static and
continuous agitation and results in a greater cardiomyocyte
differentiation efficiency. With respect to the initial medium volume,
ourfindings are similar to those of Dos Santos et al. (2011b), who also
found that by adding only 50%of the finalworking volume during the
first 24 h (the attachment period), there was an increase in cell
attachment resulting in a reduced lag phase.
Regulatory approval of any therapeutic is dependent, in part, on
the development of consistent manufacturing processes (FDA, 2009),
and therefore process development efforts should be directed toward
minimizing variation. This will also increase cost-effectiveness of
cell-based therapy manufacture. Our earlier work in T-flasks
(Heathman et al., 2015b) and spinner flasks (Heathman et al., 2015a)
showed a significant process improvement with serum-free medium
compared to a serum basedmedium (>250% increase in yield in the
serum-free medium). Here, the same effect on process yield (Fig. 9)
and consistency (Fig. 10) has been demonstrated in the ambr15.
Previous studies have also demonstrated that process automation can
improve consistency for both hMSCs and hESCs, but this work has
been predominantly limited to monolayer culture (Thomas et al.,
2007, 2009). A similar improvement has been shown here with the
better control provided by the ambr15 improving process consistency
compared to spinner flasks in both serum containing (Fig. 8) and
serum-free media (Fig. 10).
Clearly, both changes are important and Figure 10 gives some
indication of the synergy from using both. For example, while the
use of the automated ambr15 systems, with its improved control
compared to the spinner flask, reduces the CVon cell density in the
serum containing medium from 7.65% to 4.08%, the switch to
Figure 9. Growth kinetics of hMSC donor 1 cells for serum-free (SFM) and fetal bovine serum (FBS)-based media in both the ambr15 and spinner flasks with data showing (A)
the viable cell density, (B) specific growth rate, (C) the cumulative population doublings, and (D) the doubling time. Data showmean SD, n¼ 12. The arrows in (A) indicate the point
at which additional microcarriers were added to the culture for both the SFM and FBS processes.
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serum free reduces these two values to 1.06% and 0.54%,
respectively; a total of 12 replicates were used to calculate the CV.
Thus the combination of both serum-free and automated
processing improves the consistency more than 10-fold. This
improvement has clear advantages for both autologous and
allogeneic bioprocess development with reduced costs and
improved efficiency. Additionally, if processes can be effectively
scaled down, this enables larger amounts of data to be collected
during development, thereby improving process understanding
which facilitates validating future comparability studies if process
changes need to be made. If the data collection and analysis of
development efforts can be automated, this will lead to significant
time and cost savings and will reduce errors. Moreover, the
significant increase in yield associated with serum-free expansion
reduces the process time required to achieve a particular batch size,
which should also reduce overall process cost. Although not widely
explored in the literature, it is thought that the use of a serum-free
medium improves yield and consistency in comparison to serum-
based cultures due to the activation of specific growth factors in the
former, in particular platelet-derived growth factors (Heathman
et al., 2015b; Veevers-Lowe et al., 2011).
Although this study focused on culture parameters such as
intermittent agitation and initial medium volume, the major utility
of the ambr15 microbioreactor system is its use as an effective high-
throughput process development platform. This feature will enable
the study of other key culture parameters such as pH, dO2
concentration, growth media, dissociation reagents and cell, and
microcarrier inoculation density among others, thereby expediting
adherent cell/microcarrier process development.
Conclusions
Microbioreactors play an important role in process development of
therapeutics including cell-based therapies by reducing the cost and
time associated with development. This study describes the
approach taken to make the ambr15 microbioreactor amenable for
hMSC microcarrier culture and the subsequent bioprocess
development using the system. The improved process developed
using the ambr15, which included an intermittent agitation strategy
and 50% final working volume for the first 24 h, significantly
increased the yield and was subsequently validated using a larger-
scale spinner flask culture. Moving toward serum-free expansion
using the improved process increased the yield by >250% in
comparison to serum-based culture and, in conjunction with the
automated capability of the ambr, improved process consistency
10-fold compared to manually-operated spinner flask serum-based
culture. Cell identity and quality with respect to immunphenotypic
expression, multipotency and CFU-f potential was retained with the
improved process, although impact on specific CQAs for different
cell therapy products would need to be addressed depending on the
intended clinical indication. Nonetheless, this study demonstrates
that the ambr15 microbioreactor system is an effective tool for
bioprocess development and optimization of hMSC microcarrier
culture processes.
This study has been funded by the Engineering and Physical Sciences
Research Council via the E-TERM Landscape Fellowship programme (grant
no. EP/I017801/1).
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